Kornimate/medical-research-clean huggingface dataset:
comprehensive functional assessments for nocad

Conditions: Coronary Artery Disease; Myocardial Ischemia; Coronary Microvascular Dysfunction

Summary: to validate and investigate the efficacy of comprehensive functional assessments for the diagnostic and prognostic value in nocad.


Eligibility criteria:
inclusion criteria: 1. visual evaluation of epicardial coronary artery diameter stenosis (ds%) ≤ 50%; 2. czt-spect was successfully conducted within three days of cag exclusion criteria: 1. had flow-limiting epicardial stenosis (ds% \>50%) or angiography-derived ffr (angio-ffr) ≤ 0.8; 2. severe valvular heart disease; 3. chronic heart failure and/or left ventricular ejection fraction (lvef) of \< 50%; 4. cardiomyopathy and myocarditis; 5. severe renal or hepatic insufficiency; 6. failure in detecting spect; 7. failure in computing angio-imr, and -ffr.
wearable technology data driven digital health coaching (activation)- a mixed-methods study

Conditions: Elevated Blood Pressure; Hypertension; Overweight/obesity; Type 2 Diabetes Mellitus (T2DM); Hyperlipidemia; Prediabetes

Summary: public health priorities have shifted towards disease prevention, emphasising health promotion and lifestyle interventions to reduce disease burden. despite global efforts, the prevalence of chronic diseases remains high, with lifestyle factors such as alcohol consumption, diet, smoking, obesity, and sedentary behaviour playing significant roles. in singapore, suboptimal lifestyle behaviours are common, contributing to a high incidence of chronic conditions. metabolic syndrome (mets), linked to obesity, poses a growing societal burden due to its association with cardiovascular risks. disparities exist in the delivery of lifestyle interventions among healthcare providers (hcps), with many patients receiving inadequate guidance. digital health coaching, incorporating wearable technology, offers promising solutions to bridge these gaps, providing personalised, real-time support and feedback to improve lifestyle behaviours and prevent disease progression. challenges such as time constraints, lack of feedback, and limited support can be addressed through remote monitoring and tailored interventions, making scalable population-level interventions feasible.


Eligibility criteria:
inclusion criteria: * 21-75 years old * patients who are at risk of any of the following: 1. elevated blood pressure 2. overweight (bmi\>=23kg/m2) 3. pre-diabetes, or * patients who have one or more of the following (hold) conditions: 1. hypertension 2. obesity (bmi\>=27.5kg/m2) 3. hyperlipidemia 4. type 2 diabetes mellitus * patients who own a smartphone * patients who are willing to wear a smartwatch during the intervention period. exclusion criteria: * patients who have a medical condition that prevented participation in physical activity * patients who have current diagnosis or history of eating disorder, depression * patients who are currently pregnant or planning to become pregnant in the next 6 months * patients who are currently participating in a weight loss programme (commercial, medically supervised, or research study) * patients who are on weight loss medications (over-the-counter or prescription) * patients who are not mentally-, physically- or technologically-capable * patients who is unable to provide informed consent.

Keywords: digital health intervention health coaching personalisation nudging wearables
effectiveness of a cognitive and physical intervention to reduce head and muscle pain in a large population

Conditions: Migraine; Tension Type Headache; Cervical Pain

Summary: this study is an interventional trial to evaluate the effectiveness of a cognitive and physical program (intervention), in reducing the frequency of head and neck pain in the population of an extensive territory of italy.

in a previous non-randomized-controlled study in which the cognitive and physical programme was applied to a consistent number of office workers, a significant reduction of frequency of pain in the head and neck areas and of analgesic drug consumption was obtained. the results were stable at a 12 month follow up. more recently a controlled, cluster randomised, interventional trial was conducted on 1930 local government employees of the municipality of turin. the data obtained confirm those of the previous studies. the present study was designed to confirm the data in a much more extensive population , that is, residents of the italian region piemonte (piedmont) who will apply to participate. primary objective is to confirm the effectiveness of the cognitive and physical programme (intervention), in reducing the frequency of pain involving the head and neck area in a large population of a territory. secondary objective is to confirm the effectiveness of the intervention, in reducing analgesic drugs consumption after the intervention in the same population.

Eligibility criteria:
inclusion criteria: * all residents of the region piemonte (italy) may apply for recruitment exclusion criteria: * because of the pragmatic design, no exclusion criteria are required for this study

Keywords: headache cervical pain cognitive treatment relaxation exercise
postoperative delirium in the icu setting of an eastern european centre

Conditions: Postoperative Delirium; Cognitive Impairment

Summary: the study targets postoperative delirium in patients undergoing major abdominal surgery, with the aim to evaluate the functional baseline and proteomics implicated in pathogenesis, prevention strategies (such as anesthesia depth monitoring) and incidence in certain population groups.


Eligibility criteria:
inclusion criteria: * asa risk i-iii; * patients undergoing complex digestive surgery, such as esophagectomy, total gastrectomy, hemicolectomy, cephalic duodenopancreatectomy, hepatic resection. exclusion criteria: * the impossibility of obtaining the patient's consent/his decisional incapacity; * patients who underwent neurosurgery for cerebrospinal lesions / cardiac surgery under cardiopulmonary bypass; * prediagnosed senile/vascular/mixed dementia.

Keywords: postoperative delirium abdominal surgery malondialdehyde s100b protein tau protein pnf-h bispectral index anesthesia depth general anesthesia
performance evaluation of a urine-based methylation assay for urothelial carcinoma

Conditions: Urothelial Carcinoma

Summary: urothelial carcinoma (uc) is the most common malignancy of the urinary system. hematuria is a significant clinical manifestation of uc, often diagnosed through invasive procedures. urine dna methylation testing is a promising non-invasive method for early uc detection. to evaluate the sensitivity and specificity of urine dna methylation testing for detecting uc, using standard clinical and pathological diagnoses as the gold standard.

urothelial carcinoma (uc) is the most common malignancy of the urinary system, and early detection and diagnosis are crucial for patient prognosis. hematuria is a significant clinical manifestation of uc, but its diagnosis often relies on invasive procedures and imaging, posing a substantial burden on patients. with the advancement of molecular biology techniques, urine dna methylation testing has emerged as a non-invasive and highly sensitive method for early uc detection. this study aims to evaluate the performance of urine dna methylation testing in detecting uc in patients with hematuria. all patients with hematuria will receive standard clinical diagnosis, including examinations, tests, surgeries, and pathological assessments to determine the presence of uc. these clinical diagnoses will serve as the gold standard to evaluate the sensitivity and specificity of urine dna methylation testing in detecting uc in patients with hematuria. to ensure accuracy and reliability of the results, select a subset of samples with known test results for external methylation sequencing. authorized researchers will unblind the samples, and the statistical team will analyze the results, calculating sensitivity, specificity, positive predictive value, and negative predictive value of the urine dna methylation test.

Eligibility criteria:
inclusion criteria: * aged between 18 and 90 years, with gross or microscopic hematuria. * able to provide enough urine for testing before surgery. * consent to participate in the study and sign the informed consent form. exclusion criteria: * with history of any malignancies (including urothelial carcinoma). * severe urinary tract infection leading to sepsis. * patients with indwelling catheters, nephrostomy, or cystostomy. * severe liver or kidney failure or other conditions deemed unsuitable for the study. * samples with insufficient dna content or other quality control failures. * incomplete clinical or pathological data. * patients currently undergoing intravesical or systemic chemotherapy, radiotherapy, immunotherapy, or targeted therapy.

Keywords: urothelial carcinoma hematuria dna methylation
sevelamer, fetuin-a and endothelial dysfunction in ckd

Conditions: Vascular Diseases

Summary: vascular calcification and endothelial dysfunction (ed) contribute to the development of cardiovascular disease (cvd) in patients with chronic kidney disease (ckd). sevelamer, a non-calcium based phosphate binder, has been shown to attenuate cardiovascular calcification in ckd patients while the exact mechanism has not been clarified. this study was designed to investigate the effect of short-term sevelamer treatment on both serum fetuin-a concentrations and ed seen in ckd patients.

ckd stage 4 patients older than 18 years of age and willing to participate to the study were screened. those who had serum phosphorus \> 5.5 mg/dl were evaluated for the study. patients with diabetes mellitus, history of coronary artery disease, smokers and those taking statins or renin-angiotensin blockers were excluded because of the effect of these factors on endothelial dysfunction. of 62 screened patients 50 met the study criteria and were included in this study. thirty-two healthy subjects were studied as controls. the ethical committee of gulhane school of medicine approved the study and written informed consent was obtained from all patients. study design: this was a randomized study conducted from 2005 through 2006 in gulhane school of medicine. the outpatient clinic of department of nephrology is a tertiary referral center. at admission, most patients were untreated (including phosphate binders) or treated only with antihypertensive agents. after the first evaluation, patients receiving phosphate binders (n=9) underwent a 2-week washout period. patients who developed a phosphate level \>5.5 mg/dl during this period were included in the study. patients were randomly assigned in 1:1 ratio to receive sevelamer (renagel capsule) or calcium acetate (phos ex tablet). the treatment phase was 8 weeks. during the study period serum calcium and phosphorus concentration were measured every 2 weeks and the dose of phosphate binders were titrated to achieve a serum phosphorus concentration \< 5.5 mg/dl. the starting dose for sevelamer was 1-2 capsules (800 mg) three times a day and for calcium acetate (1000 mg) 1 tablet three times a day. the medications were given with meal and the doses were increased as needed. patients were not given calcitriol during the study period. fasting blood samples were taken before and after the study to measure serum creatinine, serum albumin, hs-crp, insulin, ipth, lipid profile and serum fetuin-a concentration. additionally, flow-mediated dilatation (fmd) was also evaluated before and after the study.

Eligibility criteria:
inclusion criteria: * ckd stage 4 patients * older than 18 years of age * non-diabetic * serum phosphorus \> 5.5 mg/dl exclusion criteria: * diabetes mellitus * history of coronary artery disease * smokers * taking statins or renin-angiotensin blockers

Keywords: this study was designed to investigate whether the suggested beneficial effects of sevelamer on vc were related to fetuin-a levels in patients with ckd.
the antihypertensives and vascular, endothelial and cognitive function trial

Conditions: Cognitive Impairment; Hypertension; Aging

Summary: the purpose of this study is to examine the effects of blood pressure medications on cognition and blood flow in hypertensive elderly patients with cognitive impairment. the hypothesis is that treatment with an angiotensin receptor blocker (arb) or an angiotensin-converting enzyme inhibitor (acei) will be associated with a slower rate of further cognitive decline, improved cerebral blood flow and its regulation, and preserved physical function as compared to treatment with a diuretic (hctz), independent of blood pressure level.

there is mounting evidence that hypertension, which affects more than 65% of the us elderly population, accelerates cognitive decline and increases the risk of functional disability among older individuals. hypertension is also associated with cerebral blood flow reduction and dysregulation which contribute to further cognitive and functional impairment. drugs that inhibit angiotensin ii (acei and arb) are commonly used antihypertensives and may have a protective effect on cognitive function, cerebral blood flow and physical function compared to other antihypertensives such as hydrochlorothiazide (hctz). a total of 100 individuals will be recruited for this pilot 3-arm randomized study to investigate the effects of: (i) 12 months treatment with candesartan (arb) compared to hydrochlorothiazide (hctz) and (ii) 12 months treatment with lisinopril (acei) compared to hctz and (iii) to estimate the effect size difference between lisinopril and losartan on cognition, cerebral blood flow regulation, and functional measures in a sample of elderly hypertensive individuals with objective evidence of cognitive impairment.

Eligibility criteria:
inclusion criteria: * 60 years or older * hypertension * cognitive criteria: score either 10 or less out of 15 for the executive clock draw test 1 (clox1) or less than or equal to 1 standard deviation from the corresponding age specific mean on the immediate memory subtest exclusion criteria: * intolerance to acei or arb * history of congestive heart failure * history of diabetes mellitus * history of stroke (less than 6 months)

Keywords: cognitive disorders angiotensin receptor blockers
study to assess prevalence of brca1 and brca2 mutation among ovarian, primary peritoneal and fallopian tube cancer patients in india

Conditions: Ovarian Cancer

Summary: this is a non-interventional, cross-sectional, multicentre, observational study planned to be conducted at 15 sites across all geographical regions of india. the study targets to enrol 240 patients with approximately 16 patients from each site. written approval of independent ethics committee (iec)/ institutional review board (irb) and written informed consent from willing patients will be obtained prior to the start of the study.

this is a non-interventional, cross-sectional, multicentre, observational study to be conducted at 15 sites from different geographical regions across india. the study targets to enrol 240 patients with nearly 16 patients per site over 6 months. the study will enrol females with diagnosis of ovarian, primary peritoneal, or fallopian tube cancer. no study medication will be prescribed or administered as a part of study procedure. the study will start only after obtaining written approval of independent ethics committee (iec) / institutional review board (irb) and written informed consent of the patient. the study will start only after obtaining written approval of independent ethics committee (iec) / institutional review board (irb) and written informed consent of the patient. eligible patients will undergo physical examination and data of demographics, vital signs, present/ past history of illness, family history of breast/ovarian cancer, current and previous chemotherapy regimen and current medication will be collected.

Eligibility criteria:
inclusion criteria: 1. patients who provide written informed consent 2. female ≥ 18 years of age 3. previously or newly diagnosed ovarian, primary peritoneal, or fallopian tube cancer patients. exclusion criteria: 1. patient with any medical condition that, in the opinion of the investigator, would interfere with safe completion of the study

Keywords: brca, ovarian cancer, fallopian tube cancer
vinpocetine inhibits nf-κb-dependent inflammation in acute ischemic stroke patients

Conditions: Stroke; Immunoregulation; Inflammation; Vinpocetine

Summary: immunity and inflammation play critical roles in the pathogenesis of acute ischemic stroke. therefore, immune intervention, as a new therapeutic strategy, is worthy of exploration. here, investigators tested the inflammation modulator, vinpocetine, for its effect on the outcomes of stroke. for this multi-center study, investigators recruited 60 patients with anterior cerebral circulation occlusion and onset of stroke that had exceeded 4.5 hours but lasted less than 48 hours. these patients, after randomly division into two groups, received either standard management alone (controls) or standard management plus vinpocetine (30 mg per day intravenously for 14 consecutive days, gedeon richter plc., hungary).


Eligibility criteria:
inclusion criteria: * \>18 years of age * anterior-circulation ischemic stroke: all patients had symptoms of focal neurological deficits and simultaneous radiological evidence (magnetic resonance imaging, mri) of an ischemic brain lesion * measurable neurological deficit (nihss \> 5) * interval between symptom onset and admission more than 4.5 hours and less than 48 hours. that is, all patients we recruited were beyond the 4.5 hours of symptom onset and, therefore, past the accepted time-window for thrombolytic therapy exclusion criteria: * hemorrhagic stroke and severe hemorrhage in other organs * other diseases of the central nervous system (cns) * diabetes mellitus * tumor or hematological systemic diseases * any infection before acute ischemic stroke * concomitant use of antineoplastic or immune modulating therapies * contraindication to mri
autologous hair follicle derived secretome as adjunct to aesthetic procedures

Conditions: Post Procedural Erythema

Summary: non-interventional, multi-site, prospective, open-label, observational, real-world study of autologous hair follicle secretome use.

this non-interventional, observation study is to collect real-world data on the use of an autologous, hair follicle derived secretome topical cosmetic product following various medical aesthetic procedures.

Eligibility criteria:
inclusion criteria: * male and female, * ages: 18-60 * any fitzpatrick skin type * planning a medical aesthetic procedure * planning to use ahfs cosmetic product exclusion criteria: * pregnant or breastfeeding * participation in an interventional clinical trial in the last 30 days * use of other topical cosmetic products that may confound results * use of retinoids within 7 days prior to facial procedure * any health condition that in the investigator's opinion should preclude participation in study
a study of rituximab alternative dosing rate in patients with previously untreated diffuse large b-cell or follicular non-hodgkin's lymphoma (rate)

Conditions: Non-Hodgkin's Lymphoma

Summary: this was a prospective, open-label, phase iii, multicenter, single-arm trial designed to assess the safety, pharmacokinetics, and pharmacodynamics of an alternative dosing rate of rituximab in previously untreated patients with diffuse large b-cell lymphoma (dlbcl) and follicular non-hodgkin lymphoma (nhl).


Eligibility criteria:
inclusion criteria: * written informed consent * age ≥ 18 years * patients with previously untreated diffuse large b-cell lymphoma (dlbcl) who are scheduled to receive rituximab 375 mg/m\^2 plus chop (cyclophosphamide, hydroxydaunorubicin \[also called doxorubicin or adriamycin\], oncovin \[vincristine\], prednisone or prednisolone) chemotherapy, or previously untreated follicular non-hodgkin lymphoma (nhl) who are scheduled to receive rituximab 375 mg/m\^2 plus cvp (cyclophosphamide, vincristine, prednisolone) chemotherapy * eastern cooperative oncology group (ecog) performance status 0-2 exclusion criteria: \* clinically significant cardiovascular disease (eg, uncontrolled hypertension, myocardial infarction, unstable angina), new york heart association (nyha) classification grade ii or greater congestive heart failure, a ventricular arrhythmia requiring medication within 1 year prior to day 1, or nyha grade ii or greater peripheral vascular disease on day 1 (first day of treatment) patients who meet any of the following criteria will be excluded from further study participation after cycle 1: * circulating lymphocyte count \> 5,000/μl before the cycle 2 rituximab infusion * development of a serious and/or grade 3 or 4 adverse event during cycle 1 judged by the investigator to be related to the rituximab infusion * prior premedication with additional corticosteroids other than the prednisone included in the chemotherapy regimens

Keywords: follicular nhl nhl large b-cell nhl
japanese study with rimonabant in obese type 2 diabetic patients on diet and exercise

Conditions: Obesity; Diabetes Mellitus Type 2

Summary: the primary objective of this study is to assess the efficacy of rimonabant (sr141716) compared to placebo on change in hba1c and on relative change in body weight over 36 weeks in obese type 2 diabetic patients inadequately controlled with diet and exercise alone. the secondary objectives are: * to evaluate the effect of rimonabant compared to placebo on other parameters related to the glucose control, waist circumference, body mass index and metabolic parameters; * to evaluate the safety and tolerability of rimonabant compared to placebo; * to evaluate the pharmacokinetics of rimonabant.

the total duration per patient will be approximately 53 weeks including a 36-week double-blind treatment period.

Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus patients inadequately treated with diet and exercise alone (not drug treated) * hba1c ≥ 7.0 % and ≤ 10.0 % * body mass index ≥ 25 kg/m² exclusion criteria: * type 1 diabetes * within 12 weeks prior to screening visit: use of oral antidiabetic drugs and/or insulin, of anti-obesity drugs or other drugs for weight reduction * within 4 weeks prior to screening visit: administration of systemic long-acting corticosteroids or prolonged use (more than one week) of other systemic corticosteroids, change in lipid lowering treatment * secondary obesity * primary hyperlipidemia * positive serum pregnancy test in females of childbearing potential the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Keywords: obese diabetes cannabinoid-1 receptor